Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Investors should monitor R&D updates closely, as Merck's future hinges on new drug developments amid looming patent expirations. Keytruda is now under threat not only from patent expiries but also ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

Despite the upcoming headwind that will be generated by Keytruda's loss of patent protection, the odds are good that Merck will be able to provide decent returns to its shareholders up to the ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

The company also has a solid dividend record. Its payouts have increased by 71% in the past decade, and it currently offers a ...

Cash receipts from customers in Q1 FY25 were $20k. During the quarter, Immutep received a €2,194,918 (~A$3,602,362) research ...